Skip to main content
    T

    Transcode Therapeutics Inc (RNAZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.68
    +0.05 (+3.07%)

    Market Cap: $27.60M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(8/16)
    Avg Surprise
    -204.88%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 14
    		$-7.17N/AN/ABeat-39.8%
    Mar 26
    Reported Apr 15
    		$-21.28N/AN/ABeat+98.3%
    Dec 25
    Reported Feb 25
    		$-16.42N/AN/ABeat+98.7%
    Sep 25
    Reported Nov 14
    		$-5.82$-1.02-470.59%Miss+96.1%
    Jun 25
    Reported Aug 14
    		$-5.13$-1.64-212.80%Miss+100.0%
    Mar 25
    Reported May 14
    		$-1286.15$-89.88-1330.96%Miss-114.1%
    Dec 24
    Reported Mar 28
    		$-1286.15$-89.88-1330.96%Miss-105.0%
    Sep 24
    Reported Nov 14
    		$-147.84N/A+67.35%Beat+99.8%
    Jun 24
    Reported Aug 14
    		$-27350.42$-21436.81-27.59%Miss+77.5%
    Mar 24
    Reported May 15
    		$-600.60N/A+97.68%Beat-157952.6%
    Dec 23
    Reported Mar 29
    		$-627.33$-356.40-76.02%Miss+99.8%
    Sep 23
    Reported Nov 14
    		$-62092.84$-55440.03-12.00%Miss+74.5%
    Jun 23
    Reported Aug 14
    		$-121598.47$-125294.48+2.95%Beat+54.3%
    Mar 23
    Reported May 15
    		$-0.38$-0.38+0.00%Beat-72.7%
    Dec 22
    Reported Mar 30
    		$-288288.17$-280896.17-2.63%Miss-69.6%
    Sep 22
    Reported Nov 14
    		$-243936.15$-295680.18+17.50%Beat-121967975.0%
    Jun 22
    Reported Aug 15
    		$-266112.16$-221760.13-20.00%Beat-52178954.9%
    Mar 22
    Reported May 16
    		$-0.22$-0.25+12.00%Beat-
    Dec 21
    Reported Mar 31
    		$-170016.10$-184800.11+8.00%Beat-
    Sep 21
    Reported Nov 15
    		$-0.20N/AN/ABeat-
    Jun 21
    Reported Jul 9
    		$0.51$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.03EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-59.30%ROIC124.43%
    Financial Health
    Debt/Equity-0.02xInterest CoverageN/A
    Current Ratio1.97xQuick Ratio1.97x
    Trading Statistics
    Beta1.26Avg Volume53.34K
    52-Week High$15.4952-Week Low$1.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.70
    SMA 20$1.70
    SMA 50$2.33
    SMA 200$6.53
    EMA 10$1.71
    EMA 20$1.79
    EMA 50$2.62
    EMA 200$5.78

    MACD

    Line: -0.20Signal: -0.28Hist: 0.08

    ADX

    ADX: 18.9+DI: 21.2-DI: 18.5

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down68.0
    PSAR$2.10

    Bollinger Bands

    Upper Band$1.84
    Lower Band$1.55
    %B Position1757%(Upper)
    Band Width0.45

    RSI (14-Day)

    Neutral
    39.9

    Momentum Oscillators

    Stoch %K29.6
    Stoch %D27.9
    Williams %R-62.8
    ROC (10d)3.1%
    Momentum0.05
    CCI (20d)-16.3
    MFI (14d)52.7

    Volatility Measures

    ATR (14d)$0.22(13.3%)
    StdDev (20d)0.07
    Hist Vol90.7%(High)

    Volume Flow

    VWAP$1.71
    OBV145.5M
    AD Line34.6B
    CMF (20d)-0.382

    Volume Metrics

    Avg Vol (20d)56.7K
    Vol Ratio1.0x
    VWMA (20d)$1.71

    Pivot Points

    R3$2.10
    R2$2.00
    R1$1.82
    Pivot Point$1.72
    S1$1.54
    S2$1.44
    S3$1.26

    Advanced Oscillators

    TSI-29.24
    Ultimate Osc40.6
    KST-179.63

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$-284,482$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0$284,482$0$0$0N/A$0
    Operating Expenses$6.79M$17.76M$16.03M$4.56M$4.22M$3.17M$5.09M$2.17M$5.11M$3.29M$4.10M$5.31M
    R&D$3.69M$15.53M$5.48M$3.16M$2.57M$2.22M$3.64M$1.23M$3.08M$1.76M$3.36M$3.34M
    SG&A$2.54M$2.22M$1.76M$1.40M$1.66M$951,652$1.45M$938,026$2.03M$1.53M$733,961$1.97M
    Operating Income$-6,789,505$-17,755,029$-16,026,558$-4,561,200$-4,221,134$-3,171,179$-5,092,387$-2,165,412$-5,113,916$-3,288,982$-4,097,587$-5,310,252
    Interest Income$52,168$91,888$78,757$147$148$146$159$179$178$168$138$131
    Interest Expense$0$0$542$5,960$0$114$1,833$10,792$4,482$9,706$17,345$17,282
    Income Before Tax$-6,749,828$-17,553,762$-13,217,042$-4,856,051$-4,276,502$-12,085,413$-5,915,958$-2,321,387$-5,190,814$-3,326,812$-4,087,546$-5,299,962
    Income Tax Expense$300$231,309$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,750,128$-17,785,071$-13,443,110$-4,856,051$-4,276,502$-12,085,413$-5,915,958$-2,321,387$-5,190,814$-3,326,812$-4,087,546$-5,299,962
    EBITDA$-6,778,059$-17,621,714$-13,250,477$-4,845,457$-4,263,208$-12,034,271$-5,791,429$-2,183,253$-5,043,676$-3,175,627$-3,930,166$-5,144,028
    EBIT$-6,801,996$-17,645,650$-13,295,257$-4,850,238$-4,276,650$-12,085,445$-5,914,284$-2,310,774$-5,186,510$-3,317,274$-4,070,339$-5,282,811
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RNAZ

    News

    RNAZ Forecast — Price Target — Prediction for 2027

    This article provides a forecast and various financial data for TransCode Therapeutics, Inc. (RNAZ) stock. It covers the current stock price, historical performance, market capitalization, earnings reports...

    TradingView•10/5/26•Somewhat-Bearish

    TransCode Therapeutics Prepays $841K; Yorkville Waives Amortization Event on Notes Through Oct 31

    TransCode Therapeutics prepaid $840,975 to Yorkville on October 1, 2026, consisting of principal, premium, and interest, under their convertible notes agreement. This prepayment secures a waiver from Yorkville...

    TradingView•10/2/26•Somewhat-Bullish

    Form 8K Transcode Therapeutics Inc For: 1 October

    This article reports that Transcode Therapeutics Inc. filed a Form 8K on October 1st. The filing pertains to the company's financial activities and is listed under the stock symbol RNAZ...

    Investing.com India•10/1/26•Neutral

    TransCode Therapeutics makes $840,975 prepayment under convertible notes agreement

    TransCode Therapeutics (NASDAQ: RNAZ) has made a prepayment of $840,975 to YA II PN, Ltd. under its convertible notes agreement. This prepayment was made to secure a waiver from Yorkville, the investment firm...

    Investing.com•10/1/26•Somewhat-Bearish

    Form 8K Transcode Therapeutics Inc For: 1 October By Investing.com

    This article reports on Transcode Therapeutics Inc.'s Form 8K filing for October 1st. The brief piece indicates that the filing pertains to financial information for the specified date and includes the stock symbol RNAZ....

    Investing.com Nigeria•10/1/26•Neutral

    RNAZ Valuation and Fair Value

    P/E
    -0.0x
    P/B
    -0.1x
    See GNG's fair value

    RNAZ Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    124.4%
    ROE
    -59.3%

    RNAZ Competitors

    CompanyTicker
    MIRA Pharmaceuticals, Inc. Common StockMIRA
    OneMedNet Corp.ONMD
    Evoke Pharma IncEVOK
    Plus Therapeutics IncPSTV
    Sangamo Therapeutics IncSGMO
    India Globalization Capital IncIGC
    Picard Medical, Inc.PMI
    SRx Health Solutions Inc.SRXH

    Sector: Healthcare

    RNAZ Bull Case vs Bear Case

    Bull case

    • RNAZ earns a 124.4% return on invested capital.

    Bear case

    • RNAZ beat EPS estimates in 25.0% of its last 8 reported quarters.

    RNAZ Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -410.5%

    Frequently Asked Questions About RNAZ

    Does RNAZ pay dividends?

    Transcode Therapeutics Inc (RNAZ) does not currently pay a regular dividend.

    What is RNAZ's market cap?

    Transcode Therapeutics Inc (RNAZ) has a market capitalization of $27.60M with a current stock price of $1.68.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In